Executive Series: Bionomics Limited (BNO) CEO, Dr Deborah Rathjen
CommSec's Tom Piotrowski speaks with Bionomics Limited (BNO) CEO, Dr Deborah Rathjen about:
- BNO’s key programs including the group’s anxiety and Post Traumatic Stress Disorder treatment – BNC210, and cancer treatments BNC101 and BNC105 which have all continued to make recent progress.
- The progress of BNO’s agreement with Merck & Co. to develop novel drug candidates for its treatment for Alzheimer’s disease which delivered the first milestone payment of US $10 million earlier this year in February.
- BNO’s cash position which saw the group end 3Q17 with $50m, with net cash of $4.485 million generated for the 9 months to 31 March 2017
4 topics
1 stock mentioned
most popular
Equities
The quirky trend to add to your recession ready portfolio
Sara Allen,
Livewire Markets
Education
Are you missing this tax loophole?
Sara Allen,
Livewire Markets
Equities
Signs of the bottom
Ally Selby,
Livewire Markets